 CAMBRIDGE, Mass., June 24, 2021 GLOBE NEWSWIRE -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today announced that it will be added to the Russell 2000 Index at the conclusion of the Russell US Indexes annual reconstitution on June 28, 2021. 